Latest Migraine Stories

MOUNTAIN VIEW, Calif., May 26, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for LEVADEX® orally inhaled migraine drug for the potential acute treatment of migraine in adults. According to the National Headache Foundation, approximately 30 million people in the United States suffer from migraine, a debilitating neurological disorder. Common symptoms...

Precision tinted lenses have been used widely to reduce visual perceptual distortions in poor readers, and are increasingly used for migraine sufferers, but until now the science behind these effects has been unclear. Now research published in the journal Cephalalgia, published by SAGE, uses functional magnetic resonance imaging (fMRI) for the first time to suggest a neurological basis for these visual remedies.The new research shows how coloured glasses tuned to each migraine sufferer work...

New study in the Journal of Manipulative and Physiological TherapeuticsHeadache is a very common complaint, with over 90% of all persons experiencing a headache at some time in their lives. Headaches commonly are tension-type (TTH) or migraine. They have high socioeconomic impact and can disturb most daily activities. Treatments range from pharmacologic to behavioral interventions. In a study published online today in the Journal of Manipulative and Physiological Therapeutics, a group of...

AUSTIN, Texas, May 19, 2011 /PRNewswire/ -- There is good news for the 76 million Americans who experience chronic pain including migraine, back pain, fibromyalgia and arthritis. A new study reveals that an online, self-paced chronic pain management program reduces the physical and psychological burdens of this debilitating condition. The data are being presented today at the 30th Annual American Pain Society meeting. Linda S. Ruehlman, PhD, lead author and Director of Research at...

Topamax, a medication that's prescribed to patients who need help minimizing the symptoms of migraine headaches, has recently come under FDA scrutiny with regards to using Topamax for migraines while pregnant. The Consumer Justice Foundation, a free public resource available for those who need help dealing with insurance companies and large corporations, hereby announces the change in classification by the FDA regarding the use of Topamax in pregnancy. The Consumer Justice Foundation...

ARLINGTON, Va., May 11, 2011 /PRNewswire-USNewswire/ -- HealthCentral (www.healthcentral.com), the leading collection of condition-specific health and wellness sites, announced the launch of their Speakers Bureau, a program designed to give patient advocates and bloggers a public platform to spread their message of health, well-being and support. The Speakers Bureau is a collection of hundreds of highly respected health bloggers, authors, activists, and survivors whose mission is to...

Approximately 14 percent of all strokes occur during sleep, preventing many from getting clot-busting treatment, according to a study published in the May 10, 2011, print issue of Neurology®, the medical journal of the American Academy of Neurology."Because the only treatment for ischemic stroke must be given within a few hours after the first symptoms begin, people who wake up with stroke symptoms often can't receive the treatment since we can't determine when the symptoms...

WASHINGTON, May 4, 2011 /PRNewswire/ -- Cyclic heavy menstrual bleeding (HMB) has been reported to significantly impact a woman's ability to get uninterrupted sleep which can often lead to daytime fatigue and irritability.(1) According to a recent retrospective analysis of the 6-cycle pivotal trial that supported product approval, women taking LYSTEDA® (tranexamic acid) Tablets, 3.9 g/day, experienced a 0.99 mean reduction in the number of sleep interruptions over baseline (1.65)...

The World Health Organization (WHO) said on Tuesday that about half of all adults around the world suffer from headache disorders like migraines and tension headaches, and the problem has huge economic and societal costs. The WHO said headaches are widely under-recognized, under-diagnosed and under-treated, and the knowledge about them and the burdens they impose must be improved. According to WHO, 47 percent of all adults have a headache disorder and "the financial costs to society...

MOUNTAIN VIEW, Calif., May 3, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the first quarter ended March 31, 2011. The net income for the first quarter ended March 31, 2011 was $17.6 million compared to a net loss of $14.1 million during the same period in 2010. Net income for the first quarter ended March 31, 2011 was related primarily to the $34.2 million in collaboration revenue recognized from a $60.0 million upfront payment...